duteplase

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/03/29 13:40:56」(JST)

Duteplase is a plasminogen activator.^[1]

^ Malcolm AD, Keltai M, Walsh MJ (October 1996). "ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction". Eur. Heart J. 17 (10): 1522–31. PMID 8909909.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

Mori E.SourceDepartment of Behavioral Neurology and Cognitive Neuroscience, Tohoku University Graduate School of Medicine, Sendai, Japan. morie@med.tohoku.ac.jp
Annals of the New York Academy of Sciences.Ann N Y Acad Sci.2012 Sep;1268:108-12. doi: 10.1111/j.1749-6632.2012.06689.x.
Although the internationally recommended dosage of alteplase, a single-chain rt-PA, is 0.9 mg/kg, 0.6 mg/kg is the only approved dosage in Japan, and it is widely used there. Duteplase is a two-chain rt-PA, and based on findings of the duteplase trials in the early 1990s, the smaller dosage of 0.6 m
PMID 22994228

Nakashima T, Minematsu K.SourceCerebrovascular Division, Department of Medicine, National Cardiovascular Center, 5 7-1 Fujishirodai, Suita-shi, Osaka 565 8565, Japan.
Brain and nerve = Shinkei kenkyū no shinpo.Brain Nerve.2009 Sep;61(9):1003-12.
The US Food and Drug Administration (FDA) approved the use of intravenous (IV) recombinant tissue plasminogen activator (rt-PA) in 1996, on the basis of the results of the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study. IV rt-PA therapy at a dose of 0.9 mg/kg has
PMID 19803399

Percutaneous coronary intervention-related time delay, patient's risk profile, and survival benefits of primary angioplasty vs lytic therapy in ST-segment elevation myocardial infarction.

De Luca G, Cassetti E, Marino P.SourceDivision of Cardiology, Ospedale Maggiore della Carità, Eastern Piedmont University, 28100 Novara, Italy. giuseppe.deluca@maggioreosp.novara.it
The American journal of emergency medicine.Am J Emerg Med.2009 Jul;27(6):712-9. doi: 10.1016/j.ajem.2008.04.026.
BACKGROUND: Previous reports have suggested an impact of patient's risk profile and percutaneous coronary intervention (PCI)-related time delay on the benefits of primary angioplasty as compared with fibrinolysis. However, several factors, such as inappropriate interpretation and definition of delay
PMID 19751630